# Four Origins. Four Assay Strategies.

> Compare Four Peptides — Research Peptide Fundamentals — Research Peptide Fundamentals research peptides compared by biological origin, mechanism, assay type, human evidence, and limits of inference.

**CROSS-MEMBER MATRIX**

A side-by-side comparison of what each peptide is, what researchers measure, and how far each evidence base can responsibly reach.

## The comparison in plain English

These four peptides are grouped to teach research fundamentals, not because they do the same job. GHK-Cu begins with a natural tripeptide that binds copper and is studied through tissue and skin assays. KPV is a hormone fragment studied mainly through intestinal transport and inflammation models. MOTS-c is encoded in mitochondria and is studied through cellular stress, gene regulation, and muscle metabolism. CJC-1295 is engineered to activate the growth-hormone axis for an altered duration.

The strongest comparison is not “which is best?” It is “what kind of claim can each study support?” A cell assay can clarify mechanism. An animal model can test whole-organism responses. A human observational study can identify an association. A human intervention can show pharmacology or an outcome, depending on what it measures. The table keeps origin, target, assay, and evidence maturity aligned so one category is not mistaken for another.

## Origin-to-assay matrix

| Compound | Biological or design origin | Principal mechanism | Representative assay | Evidence maturity |
|---|---|---|---|---|
| [GHK-Cu](/ghk-cu) | Endogenous GHK coordinated to copper | Copper handling; matrix and broad signaling | Fibroblast collagen, skin penetration, topical observations | Cell and ex vivo evidence plus small human topical studies [1][3][5][7] |
| [KPV](/kpv) | C-terminal fragment of alpha-MSH | PepT1 uptake; NF-kB and MAPK suppression | Cytokines, tight-junction proteins, mouse colitis | Preclinical cell and animal evidence [8][9][10][11] |
| [MOTS-c](/mots-c) | Peptide encoded within mitochondrial MT-RNR1 | AMPK-linked stress signaling, nuclear translocation, CK2 | Gene expression, muscle uptake, mouse performance, biomarker | Mechanistic and animal data; human association only [13][14][16][17] |
| [CJC-1295](/cjc-1295) | Stabilized synthetic GHRH analogue; optional DAC | GHRH receptor and GH/IGF-1 axis | Hormone time course, pulsatility, serum proteomics | Early human pharmacology without approved outcome evidence [18][20][21][22] |

## Mechanism is not a maturity score

A detailed mechanism can coexist with limited clinical evidence. KPV has a named transporter and reproducible inflammatory readouts, yet no human trial in this corpus. MOTS-c has an identified direct target and a mitochondria-to-nucleus signaling model, yet external administration has not been tested for efficacy in people [10][13][17]. Conversely, CJC-1295 has human endocrine measurements, but those establish axis activation rather than anti-aging, body-composition, or performance benefit [20][21][22].

GHK-Cu sits between these examples. It has decades of laboratory work and some human topical studies, but its broadest regeneration claims arise from heterogeneous models and reviews. Skin delivery remains a central technical constraint [1][4][5][6]. Evidence maturity must be evaluated claim by claim, not assigned once to a compound as a whole.

## Delivery changes the question

Each member exposes a different delivery problem. Native GHK is hydrophilic, so crossing the skin barrier is difficult; formulation and barrier disruption can dominate the outcome [1][5]. Free KPV is small and vulnerable to degradation, motivating colon-targeted nanoparticles and hydrogels [8][9]. MOTS-c studies face unresolved human exposure questions even though endogenous levels can be measured [14][15]. CJC-1295 makes duration explicit: DAC-mediated albumin binding converts a short GHRH-derived signal into prolonged exposure [18][21].

For all four, “the peptide” is incomplete as a methods description. Chemical form, vehicle, route, model, and sampling time determine which molecule reaches which tissue and when. Those details are part of the causal claim.

## How to read the human column

Human evidence appears in three different forms. GHK-Cu has small topical or ex vivo studies, relevant to skin and formulation but not systemic use [1][3][5]. MOTS-c has an observational cohort in a medically specific population; association can improve a risk model without proving that changing the peptide changes the outcome [14]. CJC-1295 has controlled intervention studies measuring hormones and proteins, demonstrating pharmacological activity without establishing a therapeutic endpoint [20][21][22]. KPV has no human study in the supplied set.

Study design sets the ceiling on inference. The most responsible summary is not the most dramatic one; it accurately names the model, endpoint, and uncertainty.

---

Genesis Peptides Lab independently traces peptide claims from biological origin to measurable assay; it is a literature digest, not a clinic, vendor, or source of medical advice.